FIELD: biotechnology.
SUBSTANCE: invention relates to production of engineered botulinum toxins containing at least one amino acid modification, wherein said at least one amino acid modification increases isoelectric point (pI) of the engineered clostridial toxin to a value which is at least 0.2 pI units greater than pI in other respects identical unmodified botulinum toxin, and can be used in medicine.
EFFECT: obtained toxins can be effectively used in treating diseases in which therapy with botulinum toxin is indicated.
32 cl, 10 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
| SORTASE-LABELED CLOSTRIDIA NEUROTOXINS | 2020 |
|
RU2801120C2 |
| GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
| NEUROTOXINS THAT DISPLAY REDUCED BIOLOGICAL ACTIVITY | 2010 |
|
RU2582266C2 |
| CELLS HIGHLY SENSITIVE TO CLOSTRIDIAL NEUROTOXIN | 2020 |
|
RU2831112C2 |
| TREATMENT OF SKIN DISEASES | 2021 |
|
RU2840027C1 |
| NEUROTOXINS SHOWING SHORTENED BIOLOGICAL ACTIVITY | 2012 |
|
RU2646110C2 |
| NON-TOXIC POLYPEPTIDES OF CLOSTRIDIAL NEUROTOXIN FOR USE IN TREATING NEUROLOGICAL DISORDERS | 2020 |
|
RU2839368C1 |
| THERAPEUTIC FUSION PROTEINS | 2012 |
|
RU2651492C2 |
| METHOD OF PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDE | 2012 |
|
RU2673910C2 |
